We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Nintedanib administration after the onset of acute exacerbation of interstitial lung disease in the real world.
- Authors
Kato, Motoyasu; Sasaki, Shinichi; Mori, Wataru; Kohmaru, Makiko; Akimoto, Takashi; Hayakawa, Eri; Soma, Soichiro; Arai, Yuta; Matsubara, Naho Sakamoto; Nakazawa, Shun; Sueyasu, Takuto; Hirakawa, Haruki; Motomura, Hiroaki; Sumiyoshi, Issei; Ochi, Yusuke; Watanabe, Junko; Hoshi, Kazuaki; Kadoya, Kotaro; Ihara, Hiroaki; Hou, Jia
- Abstract
Nintedanib reduces the decline in forced vital capacity and extends the time to the first acute exacerbation of interstitial lung disease (AE-ILD). However, the effect of additional nintedanib administration after AE-ILD onset is unknown. This study aimed to investigate the efficacy and safety of nintedanib administration after AE-ILD development. We retrospectively collected the data of 33 patients who developed AE-ILD between April 2014 and January 2022. Eleven patients who received nintedanib after AE-ILD development and the remaining who did not were classified into the N and No-N groups, respectively. The survival time in the N group tended to be longer than that in the No-N group. The generalized Wilcoxson test revealed that the cumulative mortality at 90 days from AE-ILD onset was significantly lower in the N group. The time to subsequent AE-ILD development was significantly longer in the N group than that in the No-N group. The incidence of adverse gastrointestinal effects and liver dysfunction in the N group was 9–18%. Treatment without nintedanib after AE-ILD development and the ratio of arterial oxygen partial pressure to fractional inspired oxygen were significant independent prognostic factors in the multivariate analysis. Thus, nintedanib administration may be a treatment option for AE-ILD.
- Subjects
INTERSTITIAL lung diseases; DISEASE exacerbation; VITAL capacity (Respiration); LUNGS; PARTIAL pressure; FACTOR analysis
- Publication
Scientific Reports, 2023, Vol 13, Issue 1, p1
- ISSN
2045-2322
- Publication type
Article
- DOI
10.1038/s41598-023-39101-w